期刊
ANALYTICA CHIMICA ACTA
卷 1124, 期 -, 页码 1-19出版社
ELSEVIER
DOI: 10.1016/j.aca.2020.04.022
关键词
Aptamer; Cancer; CTCs; Electrochemical biosensors; Exosome; SELEX
资金
- Spanish Government [RTI-2018-095756-B-I00, FPU16/05670]
- Principado de Asturias Government [IDI2018-000217]
- FEDER funds
- Asociacion Espanola Contra el Cancer
The tunability of SELEX procedure is an essential feature to supply bioaffinity receptors (aptamers) almost on demand for analytical and therapeutic purposes. This longstanding ambition is, however, not straightforward. Non-invasive cancer diagnosis, so called liquid biopsy, requires collection of body fluids with minimal or no sample pretreatment. In those raw matrices, aptamers must recognize minute amounts of biomarkers that are not unique entities but large sets of variants evolving with the disease stage. The susceptibility of aptasensors to assay conditions has driven the selection of aptamers to natural environments to ensure their optimum performance in clinical samples. We present herein a compilation of the SELEX procedures in natural milieus. By revising the electrochemical aptasensors applied to clinical samples for cancer diagnosis and tracing back to the original SELEX we analyze whether aptamers raised using these SELEX strategies are being incorporated to the diagnostic devices and how aptasensors are finding their way to a market dominated by antibody-based assays. (C) 2020 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据